Corporate News & RNS

scroll down

Director+ dealing

16 January 2018

Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Sonya Ferguson
2 Reason for the notification
a) Position/status Senior Independent Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Fusion Antibodies plc
b) LEI 213800KBAYRC9VOQ9V39
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of £0.04 each in Fusion Antibodies plc
Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
160p 15,593
d) Aggregated information
- Aggregated volume
- Price
N/A
e) Date of the transaction 15 January 2018
f) Place of the transaction London Stock Exchange, AIM (XLON)

The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

Enquiries:

Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer  
   
Allenby Capital Limited Tel: +44 (0)20 3328 5656
Virginia Bull / James Reeve / Asha Chotai  
   
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Anna Dunphy Mob: +44 (0)7876 741 001

 

back to top

« back to Corporate News